机译:P2.03A-038 Pemetrexed / Carboplatin的III期试验仅在化疗-Ma've ve age-na ve ve-na ve ve-na ve veor-na ve-ve≥70岁
Department of Oncology University of Ulsan College of Medicine Asan Medical Center;
Department of Oncology University of Ulsan College of Medicine Asan Medical Center;
Hematology and Oncology Department of Internal Medicine Gachon University Gil Medical Center;
Division of Hematology-Oncology Department of Medicine Samsung Medical Center Sungkyunkwan;
Seoul National University Hospital;
Division of Medical Oncology Yonsei Cancer Center Yonsei University College of Medicine;
Chungbuk National University Hospital;
Department of Oncology University of Ulsan College of Medicine Asan Medical Center;
机译:P2.03A-038 Pemetrexed / Carboplatin的III期试验仅在化疗-Ma've ve age-na ve ve-na ve ve-na ve veor-na ve-ve≥70岁
机译:在IIIB / IV非小细胞肺癌患者和东部合作肿瘤患者中,培养基,聚光磷酸盐/贝伐单抗和磷酸盐/卡铂/贝伐单抗的随机相2试验及2
机译:II期试验Pemetrexed Plus Carboplatin患者IB-III阶段非小细胞肺癌(NSCLC)
机译:培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
机译:新型抗肿瘤药,培美曲塞和STI-571的中枢神经系统分布:外排转运系统的作用。
机译:PointBreak:培美曲塞加卡铂和贝伐单抗继之维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐珠单抗继之贝伐单抗维持治疗
机译:在IIIB / IV非小细胞肺癌患者和东方合作肿瘤患者中,培养基,聚光磷酸盐/贝伐单抗和磷酸盐/卡铂/贝伐单抗的随机阶段2试验及2